Yun Ji Lee

Yun Ji Lee

Auto-generated profile, based on publicly available information

Yun Ji Lee

Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2022 in Journal of Yeungnam Medical Science
Verified
Journal Article
Open access
PDF file
JKJuhyung Kim
Juhyung Kim
SHSoyoon Hwang
Soyoon Hwang
NHNarae Hwang
Narae Hwang
YLYeonji Lee
Yeonji Lee
HCHee Jeong Cho
Hee Jeong Cho
DBDong Won Baek
Dong Won Baek
Severe chronic neutropenia is classified as severe congenital, cyclic, autoimmune, or idiopathic. However, there is a lot of uncertainty regarding the diagnosis of severe congenital neutropenia (SCN) and chronic idiopathic neutropenia, and this uncertainty affects further evaluations and treatments. A 20-year-old man presented with fever and knee abrasions after a bicycle accident. On admission, his initial absolute neutrophil count (ANC) was 30/µL. He had no medical history of persistent severe neutropenia with periodic oscillation of ANC. Although his fever resolved after appropriate antibiotic therapy, ANC remained at 80/µL. Bone marrow (BM) aspiration and biopsy were performed, and a BM smear showed myeloid maturation arrest. Moreover, genetic mutation test results showed a heterozygous missense variant in exon 4 of the neutrophil elastase ELANE: c597+1G>C (pV190-F199del). The patient was diagnosed with SCN. After discharge, we routinely checked his ANC level and monitored any signs of infection with minimum use of granulocyte colony-stimulating factor (G-CSF), considering its potential risk of leukemic transformation. Considering that SCN can be fatal, timely diagnosis and appropriate management with G-CSF are essential. We report the case of a patient with SCN caused by ELANE mutation who had atypical clinical manifestations. For a more accurate diagnosis and treatment of severe chronic neutropenia, further studies are needed to elucidate the various clinical features of ELANE.

28 April 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
YJYoungeun Jang
Youngeun Jang
JMJoon Ho Moon
Joon Ho Moon
YLYunji Lee
Yunji Lee
JLJung Min Lee
Jung Min Lee
DBDong Won Baek
Dong Won Baek
SSSang Kyun Sohn
Sang Kyun Sohn

25 January 2026 in American Journal of Case Reports
Verified
Journal Article
Open access
YLYun Ji Lee
Yun Ji Lee
DBDong Won Baek
Dong Won Baek
BACKGROUND Histiocytic sarcoma is a rare and aggressive hematopoietic malignancy, characterized by tumor cells exhibiting features of histiocytes or dendritic cells. Extranodal involvement, particularly in the gastrointestinal tract, skin, and soft tissues, is common and often associated with aggressive clinical behavior and poor outcomes. Due to its rarity, no standardized treatment has been established. Current therapeutic approaches are generally adapted from aggressive non-Hodgkin lymphoma protocols, typically involving multi-agent chemotherapy. However, therapeutic responses are often suboptimal, with frequent relapses. In selected cases, hematopoietic stem cell transplantation has been employed following intensive chemotherapy for disease control. CASE REPORT A 44-year-old woman presented with pancytopenia and was initially diagnosed with immune thrombocytopenia. After splenectomy for refractory disease, histopathlogic examination of spleen confirmed histiocytic sarcoma. She received 6 cycles of chemotherapy with cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), etoposide, and prednisone. Despite an initial response, the disease progressed. She underwent high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, but ultimately died due to disease relapse. CONCLUSIONS This case demonstrates the highly aggressive course and poor prognosis of histiocytic sarcoma, even after intensive chemotherapy and autologous stem cell transplanatation. Given the highly aggressive nature of histiocytic sarcoma and its generally poor prognosis, allogeneic stem cell transplantation may offer a more effective strategy for achieving long-term remission, particularly in patients with relapsed or refractory disease. Large-scale studies are needed to establish treatment guidelines for histiocytic sarcoma.

1 June 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YLYun Ji Lee
Yun Ji Lee
IJInuk Jung
Inuk Jung
JBJin Ho Baek
Jin Ho Baek
JKJong Gwang Kim
Jong Gwang Kim
KPKi Bum Park
Ki Bum Park
BKByung Woog Kang
Byung Woog Kang
Purpose: Poorly cohesive cell gastric cancer has aggressive and heterogeneous characteristics. This study investigated the clinical significance of fibroblast growth factor receptor 2 expression and genetic variations in patients with PCC-GC. Materials and Methods: We retrospectively collected 209 surgically resected stage II and III PCC-GC cases. After FGFR2 immunostaining, we analyzed clinical data and performed targeted sequencing to assess their impact on patient survival. Results: Among 209 patients, 89 (42.6%) were classified as stage II and 120 (57.4%) as stage III. FGFR2 overexpression varied by stage, with FGFR2 positivity observed in 61.5% of stage II cases, while FGFR2-negative cases were predominant in stage III patients (60.1%) (P = 0.037). Moreover, lymph node involvement was associated with FGFR2 expression (P = 0.009). FGFR2 positivity significantly correlated with improved disease-free survival (DFS) and overall survival and remained an independent favorable prognostic factor for DFS in multivariate analysis (P = 0.022). Targeted next-generation sequencing was performed in five selected cases, FGFR2 amplification or pathogenic alterations were not found. Conclusion: This study shows that FGFR2 expression was independently associated with improved DFS in PCC-GC. These findings suggest that FGFR2 may serve as a prognostic biomarker in patients with PCC-GC.